Soliris (Eculizumab) for Myasthenia Gravis

Overview
Soliris is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive. Soliris is also referred to by its drug name, eculizumab.

Soliris is a member of a class of drugs called monoclonal antibodies. In treating myasthenia gravis, it’s believed to work by disrupting communication between nerves and muscles.

How do I take it?
Prescribing information states that for generalized myasthenia gravis, Soliris is administered through intravenous infusion by a health care professional. Your doctor will advise you of the dosing schedule for your condition.

Side effects
The FDA-approved label for Soliris lists musculoskeletal pain as a common side effect when used for treating generalized myasthenia gravis.

Rare but serious side effects listed for Soliris include increased susceptibility to serious meningococcal infections, other serious infections, hemolysis (destruction of red blood cells) after discontinuing the medication, and infusion-related reactions such as anaphylaxis (severe, life-threatening allergic reaction).

For more details about this treatment, visit:

Soliris — Alexion Pharmaceuticals
https://solirisgmgpro.com/

Eculizumab: A Review in Generalized Myasthenia Gravis — Drugs
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC58...